Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMAB Genmab A/S	$22.67 +3.7%	$21.75	$17.24 ▼ $27.94	$14.03B	0.95	1.13 million shs	827,040 shs
RDY Dr. Reddy's Laboratories	$14.26 +2.5%	$14.81	$12.26 ▼ $16.85	$11.61B	0.29	1.48 million shs	927,559 shs
TEVA Teva Pharmaceutical Industries	$17.21 +3.7%	$16.68	$12.47 ▼ $22.80	$19.04B	0.62	12.71 million shs	9.83 million shs
TLX Telix Pharmaceuticals	$11.18 +3.3%	$15.23	$10.70 ▼ $30.36	$3.66B	N/A	77,820 shs	110,920 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMAB Genmab A/S	+3.75%	-1.04%	+2.20%	+14.62%	-17.50%
RDY Dr. Reddy's Laboratories	+0.72%	+1.72%	-4.17%	-1.80%	-15.46%
TEVA Teva Pharmaceutical Industries	+1.02%	+5.47%	+1.16%	-0.66%	-2.93%
TLX Telix Pharmaceuticals	-0.64%	-11.75%	-32.25%	-34.02%	+1,081,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMAB Genmab A/S	3.7903 of 5 stars	3.3	3.0	0.0	0.0	3.9	0.0	3.1
RDY Dr. Reddy's Laboratories	2.5128 of 5 stars	2.5	2.0	1.7	0.0	3.3	0.0	1.9
TEVA Teva Pharmaceutical Industries	3.2222 of 5 stars	3.6	2.0	0.0	0.0	3.6	1.7	1.3
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMAB Genmab A/S	2.64	Moderate Buy	$37.80	66.74% Upside
RDY Dr. Reddy's Laboratories	3.00	Buy	$16.95	18.86% Upside
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	43.60% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	99.76% Upside

Current Analyst Ratings Breakdown

Latest TLX, TEVA, GMAB, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/8/2025	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $23.00
6/12/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00
6/6/2025	TEVA Teva Pharmaceutical Industries	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00
6/5/2025	RDY Dr. Reddy's Laboratories	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
6/5/2025	RDY Dr. Reddy's Laboratories	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$14.44 ➝ $16.90
6/5/2025	TLX Telix Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$22.00
5/28/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00
5/27/2025	TEVA Teva Pharmaceutical Industries	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMAB Genmab A/S	$3.12B	4.66	$1.57 per share	14.42	$8.26 per share	2.74
RDY Dr. Reddy's Laboratories	$3.81B	3.12	$1.06 per share	13.47	$4.94 per share	2.89
TEVA Teva Pharmaceutical Industries	$16.54B	1.19	$3.49 per share	4.93	$5.96 per share	2.89
TLX Telix Pharmaceuticals	$516.72M	7.32	$0.12 per share	94.75	$1.12 per share	9.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMAB Genmab A/S	$1.14B	$1.99	11.39	12.74	6.42	37.53%	21.03%	16.98%	N/A
RDY Dr. Reddy's Laboratories	$663M	$0.66	21.61	17.39	5.60	16.99%	17.25%	11.63%	N/A
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	6.54	0.98	-0.95%	46.10%	7.18%	N/A
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	23.29	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest TLX, TEVA, GMAB, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	N/A	N/A	N/A	$316.69 million	N/A
8/7/2025	Q2 2025	GMAB Genmab A/S	$0.39	$0.54	+$0.15	$0.54	$5.77 billion	$925.00 million
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
7/23/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.18	$0.20	+$0.02	$0.20	$88.27 billion	$988.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.49%	N/A	10.61%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMAB Genmab A/S	N/A	6.22	6.20
RDY Dr. Reddy's Laboratories	0.01	1.89	1.36
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMAB Genmab A/S	7.07%
RDY Dr. Reddy's Laboratories	3.85%
TEVA Teva Pharmaceutical Industries	54.05%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
GMAB Genmab A/S	1.54%
RDY Dr. Reddy's Laboratories	2.00%
TEVA Teva Pharmaceutical Industries	0.49%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMAB Genmab A/S	2,682	641.54 million	631.66 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.90 million	818.20 million	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

TLX, TEVA, GMAB, and RDY Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

August 13 at 11:15 AM | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena – Hagens Berman

August 12 at 1:16 PM | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Time to Sell?

August 12 at 11:09 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

August 11 at 10:00 AM | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsÂ On Behalf of Investors of Telix Pharmaceuticals Limited â€“ TLX

August 9, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

August 8, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Large Volume Increase - Time to Buy?

August 7, 2025 | marketbeat.com

ABC Arbitrage SA Takes Position in Telix Pharmaceuticals Limited (NASDAQ:TLX)

August 7, 2025 | marketbeat.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

August 6, 2025 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

August 6, 2025 | prnewswire.com

Broker says Telix shares could surge 80% higher after selloff

August 5, 2025 | msn.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

August 5, 2025 | globenewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 52-Week Low - Should You Sell?

August 5, 2025 | marketbeat.com

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

July 31, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 31, 2025 | prnewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 31, 2025 | prnewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?

July 30, 2025 | marketbeat.com

Telix H1 2025 Results: Investor Webcast Notification

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry

July 29, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

July 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLX, TEVA, GMAB, and RDY Company Descriptions

Genmab A/S NASDAQ:GMAB

$22.67 +0.80 (+3.66%)

Closing price 04:00 PM Eastern

Extended Trading

$22.74 +0.07 (+0.31%)

As of 07:46 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Dr. Reddy's Laboratories NYSE:RDY

$14.26 +0.35 (+2.52%)

Closing price 03:59 PM Eastern

Extended Trading

$14.30 +0.04 (+0.27%)

As of 07:13 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Teva Pharmaceutical Industries NYSE:TEVA

$17.21 +0.61 (+3.67%)

Closing price 03:59 PM Eastern

Extended Trading

$17.17 -0.04 (-0.21%)

As of 08:00 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Telix Pharmaceuticals NASDAQ:TLX

$11.18 +0.36 (+3.33%)

Closing price 04:00 PM Eastern

Extended Trading

$11.12 -0.05 (-0.49%)

As of 06:53 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time